title: Efficacy and perioperative timing of bromfenac in the management of ocular discomfort after femtosecond laser-assisted laser in situ keratomileusis.
abstract: To evaluate the safety, efficacy, and appropriate perioperative timing of the use of topical bromfenac ophthalmic solution 0.07% after femtosecond laser-assisted laser in situ keratomileusis (LASIK).
  
  
  
  Keil LASIK Vision Center, Grand Rapids, Michigan, USA.
  
  
  
  Prospective case series.
  
  
  
  Ocular discomfort was assessed 1, 2, and 5 hours postoperatively and the following morning using the Ocular Comfort Grading Assessment in patients treated with topical bromfenac 0.07% or artificial tears just before, just after, or before and after femtosecond laser-assisted LASIK. Visual outcomes and complications were noted up to 24 hours.
  
  
  
  The study enrolled 64 patients (120 eyes). Patients who were treated with bromfenac 0.07% just before or before and after femtosecond laser-assisted LASIK showed the greatest statistically significant decrease in several discomfort scores within the first few hours in comparison with the control group. Two hours after surgery, the majority of patients who were treated before and after LASIK were sleeping comfortably. There were no significant differences in visual acuity; 1 day postoperatively, the uncorrected distance visual acuity was 20/20 in 106 eyes (89%) and 20/25 or better in 116 eyes (97%). At 3 months, all patients had binocular distance visual acuity of 20/20 or better and 86% of patients had 20/15 or better.
  
  
  
  Ocular discomfort after femtosecond laser-assisted LASIK was reduced with a single dose of topical bromfenac 0.07% given immediately before surgery or given just before and after surgery and was typically minimal in all groups the morning after surgery.
authors.affiliation: From the Department of Neurology and Ophthalmology (Cleaveland, Keil), Michigan State University, the Department of Ophthalmology (Cleaveland, Keil), Metro Health Hospital, the Keil LASIK Vision Center (DeMann, Keil), and the Center of Social Research (Carlson), Calvin College, Grand Rapids, Michigan, USA.
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Cleaveland
authors.affiliation: From the Department of Neurology and Ophthalmology (Cleaveland, Keil), Michigan State University, the Department of Ophthalmology (Cleaveland, Keil), Metro Health Hospital, the Keil LASIK Vision Center (DeMann, Keil), and the Center of Social Research (Carlson), Calvin College, Grand Rapids, Michigan, USA.
authors.forename: Derek W
authors.initials: DW
authors.lastname: De Mann
authors.affiliation: From the Department of Neurology and Ophthalmology (Cleaveland, Keil), Michigan State University, the Department of Ophthalmology (Cleaveland, Keil), Metro Health Hospital, the Keil LASIK Vision Center (DeMann, Keil), and the Center of Social Research (Carlson), Calvin College, Grand Rapids, Michigan, USA.
authors.forename: Neil E
authors.initials: NE
authors.lastname: Carlson
authors.affiliation: From the Department of Neurology and Ophthalmology (Cleaveland, Keil), Michigan State University, the Department of Ophthalmology (Cleaveland, Keil), Metro Health Hospital, the Keil LASIK Vision Center (DeMann, Keil), and the Center of Social Research (Carlson), Calvin College, Grand Rapids, Michigan, USA. Electronic address: keilmich@yahoo.com.
authors.forename: Michael L
authors.initials: ML
authors.lastname: Keil
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001577:Benzophenones / Q000627:therapeutic use; D001969:Bromobenzenes / Q000627:therapeutic use; D006801:Humans; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects; D054018:Lasers, Excimer / Q000627:therapeutic use; D009216:Myopia / Q000601:surgery; D010146:Pain / Q000188:drug therapy; D011184:Postoperative Period; D014785:Vision, Ocular
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; C053083:bromfenac